Non Hodgkin's Lymphoma Clinical Trial
Official title:
Busulfan, Etoposide, Cytarabine and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With Diffuse Large B Cell Lymphoma (DLCBL) Previously Treated With Rituximab Based Regimen
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) including intravenous busulfan instead of BCNU of standard BEAM as a conditioning for autologous stem cell transplantation in patients with NHL.
Among the high-dose conditioning regimens commonly used in patients with NHL are BEAM (BCNU,
etoposide, cytarabine, and melphalan), BEAC (BCNU, etoposide, cytarabine, and
cyclophosphamide), CBV (cyclophosphamide, carmustine, etoposide), and combination regimen
with total body irradiation. Three-year progression free survival of patients with NHL
received above high-dose chemotherapy followed by autologous stem cell rescue was reported
as 40-50%, which is still unsatisfactory.
Busulfan (Bu)-based preparative regimens, which are commonly used with allogeneic SCT have
also been studied with ASCT for lymphomas.
The development of intravenous busulfan achieved 100% bioavailability bypassing the oral
route and increased safety and reliability of generating therapeutic busulfan levels,
maximizing efficacy.
Recently, one prospective study showed that a combination conditioning regimen of i.v.
busulfan, cyclophosphamide, etoposide was found to be well tolerated and seemed to be
effective in patients with aggressive NHL.
Another prospective study for multiple myeloma patients showed that i.v. busulfan and
melphalan conditioning regimen made no grade 3-4 non-hematological complication.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06014073 -
TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02007811 -
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination
|
Phase 1/Phase 2 | |
| Terminated |
NCT00909948 -
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
|
Phase 1 | |
| Completed |
NCT00665314 -
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
|
Phase 2 | |
| Recruiting |
NCT05370547 -
Chidamide Bridging for CAR-T Therapy
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01101581 -
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
|
Phase 1/Phase 2 | |
| Completed |
NCT00477945 -
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL
|
Phase 1 | |
| Terminated |
NCT00038818 -
CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation
|
N/A | |
| Withdrawn |
NCT01789723 -
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
|
Phase 1 | |
| Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 | |
| Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
| Terminated |
NCT00714259 -
Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies
|
Phase 2/Phase 3 | |
| Completed |
NCT01018758 -
Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy
|
Phase 2 | |
| Completed |
NCT00001830 -
Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
|
Phase 1 | |
| Completed |
NCT01527422 -
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL
|
Phase 1/Phase 2 | |
| Completed |
NCT00834951 -
Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04497688 -
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
|
N/A | |
| Completed |
NCT00597714 -
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT00001430 -
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
|
Phase 2 | |
| Active, not recruiting |
NCT01316523 -
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
|
Phase 2 |